Eliminating sleeping cancer cells

A team of 11 led by Professor Peter Croucher

Australia, Israel, USA, UK

 Biologists, immunologists, geneticists, haematologists and epigeneticists

 5 years

 

 

Dormancy Grand Challenge

The challenge: Identify and target tumour cells that remain dormant for many years after seemingly effective treatment.

Some cancers return years after treatment, claiming the lives of cancer patients – and we know that dormant cancer cells are responsible for this devastating relapse. We're so excited by the prospect of support from the Cancer Research UK Grand Challenge. This is an unprecedented opportunity to crack the problem of why some cancer cells sleep, then wake. Solving this challenge will revolutionise understanding of cancer and bring new meaning to a “cure” for cancer.

Professor Peter Croucher, Principal Investigator

Background

One of the greatest challenges facing cancer researchers today is cell dormancy. Cancer cells that were not killed by initial, seemingly effective treatment, can go to sleep and hide in a dormant state in distant organs or bones, escaping detection. Often without warning, these dormant cells can wake up many months or years later and start to form a new cancer. It is not known why or how this happens, making these returning cancers hard to predict, detect and treat.

Led by Professor Peter Croucher, an international team of cancer biologists, immunologists, geneticists, haematologists and oncologists, is hoping to answer these challenging questions. They want to know – why do cancer cells become dormant? And what causes them to wake up and form a new cancer?

Their Grand Challenge project aims to create a map of the biological environment around dormant cancer cells and the processes that control them, so that treatments can be developed to stop cancer returning. 

The Research

In a project that spans Australia, Israel, the UK and US, Professor Croucher’s team plans to create a 4D map of dormant cells and their environment, and study the genes, molecules and processes that are involved in cell dormancy and activation. Understanding the changes in the cellular and molecular ecosystem around dormant cancer cells will allow them to develop biomarkers – a way of identifying a dormant cell – and design targeted treatments that either stop cancer cells from waking up, or eliminate them completely.

The team also plans to develop data-informed computational models to predict dormant cell behaviour in the body. They will use these models to facilitate their understanding of how different treatments might affect dormant cancer cells. Their research will provide the insight needed to understand how these dormant cells can be killed.

Impact 

Previously thought to be an impossible problem to solve, because of the technical challenges in finding and studying dormant cells, this research could accelerate progress in the field of cancer dormancy research on an unprecedented scale. It could transform the way we manage and treat cancer relapses, by providing us with revolutionary new technologies and treatments that target dormant cancer cells. Ultimately, this research could help us find ways to stop an individual’s cancer from returning.

The mechanisms that allow cancer to remain dormant is a topic that has puzzled the research community and this multidisciplinary team is aiming to tackle the problem from many different angles. If successful this team could change the way we think about the field of dormancy completely and might allow for more effective tumour eradication.

Professor Brian Druker, Grand Challenge Advisory Panel 

The Team

 

Professor Peter Croucher

Grand Challenge Shortlisted Team Principal Investigator
Professor of Bone Biology

Country: Australia
Organisation: Garvan Institute of Medical Research
Discipline: Bone biology, Tumour dormancy

 

Professor Ido Amit

Professor of Immunology

Country: Israel
Organisation: Weizmann Institute of Science
Discipline: Immuno-genomics

 

Professor Susan Clark

Professor of Genomics and Epigenetics

Country: Australia
Organisation: Garvan Institute of Medical Research
Discipline: Genomics, epigenetics

 

Professor Madhav Dhodapkar

Professor of Hematology and Immunobiology

Country: USA
Organisation: Yale University
Discipline: Haematology

 

Dr Claire Edwards

Associate Professor of Bone Oncology

Country: UK
Organisation: University of Oxford
Discipline: Bone oncology

 

Professor Yibin Kang

Professor of Bone Metastasis

Country: USA
Organisation: Princeton University
Discipline: Bone metastasis

 

Dr Tri Phan

Associate Professor of Intravital Microscopy

Country: Australia
Organisation: Garvan Institute of Medical Research
Discipline: Pathology, imaging

 

Professor Wolf Reik

Professor of Epigenetics

Country: UK
Organisation: The Babraham Institute
Discipline: Molecular biology, epigenetics

 

Professor Mark Smyth

Professor of Immunology

Country: Australia
Organisation: QIMR Berghofer Medical Research Institute
Discipline: Immunology

 

Professor Sheila Stewart

Professor of Molecular Biology

Country: USA
Organisation: Washington University
Discipline: Cancer molecular biology

 

Professor Katherine Weilbaecher

Professor of Molecular Oncology

Country: USA
Organisation: Washington University
Discipline: Molecular oncology

 

Professor Andrew Zannettino

Professor of Experimental Haematology and Associate Dean of Research

Country: Australia
Organisation: University of Adelaide
Discipline: Haematology

Share this page